The present invention relates to a combination therapy for treating infections caused by Mycobacterium abscessus and other microbial pathogens in subjects with cystic fibrosis comprising the sequential, simultaneous or separate administration of pyridine-2-thiol 1-oxides or their salts and cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
A pharmaceutical combination for the treatment of lung infections in subjects with cystic fibrosis
Pasca MR;
2024-01-01
Abstract
The present invention relates to a combination therapy for treating infections caused by Mycobacterium abscessus and other microbial pathogens in subjects with cystic fibrosis comprising the sequential, simultaneous or separate administration of pyridine-2-thiol 1-oxides or their salts and cystic fibrosis transmembrane conductance regulator (CFTR) modulators.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
